publication date: May. 1, 2014

Thyroid Cancer
Oral Sorafenib Trial Published in The Lancet; Tablets Extend PFS in Metastatic Disease


Last year, a phase III trial demonstrated Nexavar (sorafenib) tablets significantly extended progression-free survival in locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.

Results from the trial, named DECISION, were recently published in The Lancet. Based on these data, Nexavar was approved by FDA in November 2013.

“The Lancet publication will give healthcare providers greater insight into the DECISION trial,” said Marcia Brose, principal investigator of the trial and assistant professor in the Department of Otorhinolaryngology: Head and Neck Surgery in the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania. “The DECISION trial demonstrates the activity of sorafenib for this type of differentiated thyroid cancer in patients with this challenging tumor.”

The trial was an international, multicenter, placebo-controlled study that evaluated 417 patients with locally recurrent or metastatic, progressive differentiated thyroid carcinoma refractory to radioactive iodine treatment.

The primary endpoint of the study was progression-free survival. Secondary endpoints included overall survival, tumor response rate, and duration of response. Safety and tolerability were also evaluated. Results were presented in a plenary session at the American Society of Clinical Oncology Annual Meeting in June 2013.

Median PFS was 10.8 months (95% CI 9.1-12.9) among patients treated with Nexavar, compared to 5.8 months (95% CI 5.3-7.8) among patients receiving placebo (HR=0.59 [95% CI, 0.46, 0.76]; p<0.001).

There was no statistically significant difference in overall survival (HR= 0.80 [95% CI, 0.54-1.19]; p=0.14). Following investigator-determined disease progression, 157 (75 percent) patients randomized to placebo crossed … Continue reading TCCL April – Thyroid Cancer

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.